Healthcare professionals in the European Union are to be issued with advice about the risk for anaphylactic reactions in patients with multiple sclerosis (MS) who are treated with glatiramer acetate. Such reactions could occur even years after the start of treatment, the European Medicines Agency (EMA) warned…
